- 49. (New) The method of claim 19 further comprising incorporating one or more deoxyribonucleotide analogs into the mRNA portion of said mRNA-cDNA hybrid.
- 50. (New) The composition of claim 23, wherein a nucleotide analog is incorporated into the cDNA portion of said mRNA-cDNA hybrid.
- 51. (New) The composition of claim 50, wherein the nucleotide analog is selected from the group consisting of uracil, inosine, xanthine, hypoxanthine, labeled nucleotide, 7-deaza-dNTP, methylthio-linked nucleotide, phosphothio-linked nucleotide, morpholino nucleotide and peptide nucleic acid (PNA).
- 52. (New) The composition of claim 50, wherein the nucleotide analog is a ribonucleotide.
- 53. (New) The composition of claim 50, wherein the nucleotide analog is a deoxyribonucleotide.
- 54. (New) The composition of claim 23, wherein one or more deoxyribonucleotide analogs is incorporated into the mRNA portion of said mRNA-cDNA hybrid.

These new dependent claims are fully supported by the specification as filed. See, for example, page 5, ll. 12-16 and the definition of "nucleotide analogs" on page 11.

FEE DUE TO FILE THIS AMENDMENT

This amendment has added 9 new dependent claims. Thus, the fees due to this amendment are 9 X \$9 for a total of eighty one dollars (\$81.00). Please charge Deposit Account No. 50-1192, Docket No. 13761-7024 in the amount of \$81.00 to cover the fees. A duplicate copy of this sheet is enclosed.

- 49. (New) The method of claim 19 further comprising incorporating one or more deoxyribonucleotide analogs into the mRNA portion of said mRNA-cDNA hybrid.
- 50. (New) The composition of claim 23, wherein a nucleotide analog is incorporated into the cDNA portion of said mRNA-cDNA hybrid.
- 51. (New) The composition of claim 50, wherein the nucleotide analog is selected from the group consisting of uracil, inosine, xanthine, hypoxanthine, labeled nucleotide, 7-deaza-dNTP, methylthio-linked nucleotide, phosphothio-linked nucleotide, morpholino nucleotide and peptide nucleic acid (PNA).
- 52. (New) The composition of claim 50, wherein the nucleotide analog is a ribonucleotide.
- 53. (New) The composition of claim 50, wherein the nucleotide analog is a deoxyribonucleotide.
- 54. (New) The composition of claim 23, wherein one or more deoxyribonucleotide analogs is incorporated into the mRNA portion of said mRNA-cDNA hybrid.

These new dependent claims are fully supported by the specification as filed. See, for example, page 5, ll. 12-16 and the definition of "nucleotide analogs" on page 11.

FEE DUE TO FILE THIS AMENDMENT

This amendment has added 9 new dependent claims. Thus, the fees due to this amendment are 9 X \$9 for a total of eighty one dollars (\$81.00). Please charge Deposit Account No. 50-1192, Docket No. 13761-7024 in the amount of \$81.00 to cover the fees. A duplicate copy of this sheet is enclosed.

Please address all correspondence regarding this communication to the following address:

Dated: May 20, 2002

Respectfully submitted,

McCutchen, Doyle, Brown & Enersen, LLP

By:

RAJIV YADAV Ph.D. Esq. Registration No.: 43,999

McCutchen, Doyle, Brown & Enersen, LLP Three Embarcadero Center, 18th Floor San Francisco, California 94111 Telephone: (415) 393-2000

Telefax: (415) 393-2286